HONG KONG – South Korean biotech venture Crystal Genomics Inc., based in Seongnam City, Gyeonggi-do, said it signed a memorandum of understanding for a strategic partnership with Bellevue Asset Management AG, a global asset manager headquartered in Küsnacht, Switzerland.
HONG KONG – Aiming to accelerate its biopharmaceutical R&D and marketing approvals, South Korea's Ministry of Food and Drug Safety (MFDS) and Ministry of Health and Welfare recently announced the Proposal of Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act had passed the country's National Assembly plenary session at the beginning of August and will come into force in a year's time.
HONG KONG – South Korea is the third biggest pharmaceutical market in Asia following China and Japan. Even though it accounts for 1.8% of the global pharmaceutical market, the country aims to launch at least two blockbuster drugs by 2030. Backed by massive support from the government, Korea's biopharmaceutical industry is focusing on R&D, production and out-licensing to make high-value new drugs.
HONG KONG – South Korea is the third biggest pharmaceutical market in Asia following China and Japan. Even though it accounts for 1.8% of the global pharmaceutical market, the country aims to launch at least two blockbuster drugs by 2030. Backed by massive support from the government, Korea's biopharmaceutical industry is focusing on R&D, production and out-licensing to make high-value new drugs.
HONG KONG – Aiming to accelerate its biopharmaceutical R&D and marketing approvals, South Korea's Ministry of Food and Drug Safety (MFDS) and Ministry of Health and Welfare recently announced the Proposal of Advanced Regenerative Medicine and Advanced Biopharmaceuticals Safety and Support Act had passed the country's National Assembly plenary session at the beginning of August and will come into force in a year's time.
HONG KONG – The trade feud between South Korea and Japan has worsened since the beginning of July, when the Japanese government said it would impose new regulations on exports to Korea. The new policies are mostly applied to elements of semiconductor technology but also includes some pharmaceutical components and devices, leading to concerns that the regulations will affect Korea's pharmaceutical sector.
HONG KONG – Daejeon, South Korea-based Alteogen Inc. said that it has signed a licensing agreement with Brazil's Cristália Produtos Químicos Farmacêuticos Ltd. to jointly develop and commercialize Alteogen's ALT-P1, a persistent growth hormone for children.
HONG KONG – Samsung Bioepis Co. Ltd., a South Korean biosimilar developer, said the FDA approved its July 2018 application for Hadlima (adalimumab-bwwd), a biosimilar referencing Abbvie Inc. blockbuster TNF-blocker Humira (adalimumab).
